Clinical Trial Update: SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]

View source ↗

Summary

An early-phase (Phase 1) trial update for SL4903 CAR-T therapy targeting relapsed/refractory multiple myeloma; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• And Refractory Multiple Myeloma
• Multiple Myeloma

Drugs mentioned

• SL4903 CAR-T Therapy

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Relapsed and Refractory Multiple Myeloma (RRMM) | EARLY_Phase 1 | Status: NOT_YET_RECRUITING